by Daniel X. Thomas
Brief outline of the cases of the EPO
EP 3 666 797 B1 relates to antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9) and methods of using and making the antigen binding proteins.
The opposition filed by compagnies of the Sanofi group and Regeneron has been rejected by the OD.
by Daniel X. Thomas
EP 3 756 767 B1 relates to modular point-of-care devices and uses thereof.
The patent derives from a third-generation divisional application ultimately deriving from the international patent application PCT/US2008/078636, with the international publication number WO2009/046227 A1.
The proprietor is Labrador Diagnostics LLC.
One of the inventors is Elisabeth Holmes from the well-known,
by Daniel X. Thomas
Through discussions on another blog, I have discovered some hard to be believe facts, which put the whole construct of the UPC on an even more shoddy basis.
In various cases, Roku has requested before the UPC-CFI LD Munich and the CoA that the UPC refers a question to the CJEU about the legal status of the UPC.
by Daniel X. Thomas
EP 3 611 581 B1 relates to an in industrial controlled and to a method configured to control an industrial activity. It derives from the parent application EP 3 249 481.
Brief outline of the case
The patent was revoked by the OD for infringement of Art 76(1), 84 and lack of IS.
by Daniel X. Thomas
For the introduction of the case, please refer to the blog entry Roku I.
In the present case, we will discuss the decision of the CoA UPC.
In this decision, the CoA considered the compatibility of the UPC’s jurisdiction with EU law and the replacement of London by Milan.
The decision of the CoA UPC has been taken in a composition of 3 LQJ.